
Product Data Sheet

Product Name: RIP1/RIP3/MLKL activator 1

Cat. No.: GC67969

Chemical Properties

Cas. No. 2682850-41-3

Formula $C_{43}H_{56}N_4O_3$ M.Wt 676.93

Solubility Storage 4°C, stored under nitrogen

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent **anti-glioma** agent. RIP1/RIP3/MLKL activator 1 induces **Necroptosis** through **RIP1/RIP3/MLKL** pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability^[1].

RIP1/RIP3/MLKL activator 1 (Compound 6i) (96 h) shows antiproliferative activities in human glioma cell lines^[1].

RIP1/RIP3/MLKL activator 1 (0-4 μM, 0-72 h) exhibits remarkable antiproliferative activity for U251 cells in a time- and concentration-dependent manner^[1].

RIP1/RIP3/MLKL activator 1 (10 μM, 0-72 h) shows acceptable stability^[1].

RIP1/RIP3/MLKL activator 1 (0-2 μM, 24 h) effectively inhibits the migration of U251 cells^[1].

RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway, and induces mitochondrial depolarization in U251 cells^[1].

RIP1/RIP3/MLKL activator 1 could not induce apoptosis in U251 cells^[1].

Cell Proliferation Assay^[1]

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell Line: A172, LN229, U87, U251 and L02 cell lines

Concentration: 0-4 μ M for U251 cells

Incubation Time: 96 h; 24, 48, and 72 h for U251 cells

Result: Showed antiproliferative activity with IC₅₀ values of 3.03 ± 0.70 , 1.78 ± 0.79 , 1.22 ± 0.89 , 0.94 ± 0.45 , and 0.99 ± 0.46 μ M against A172, LN229, U87, U251 and L02 cells, respectively. Time- and concentration-dependently inhibited the growth in U251 cells.

Western Blot Analysis^[1]

Cell Line: U251

Concentration: 0, 0.5, 1, 2, and 4 μ M

Incubation Time: 24 or 48 h

Result: Concentration-dependently upregulated the expression of p-RIP1, RIP1, p-RIP3, RIP3, p-MLKL, and MLKL at 24 or 48 h.

RIP1/RIP3/MLKL activator 1 (Compound 6i) (2.50 ng/tail; i.v.; 48 h) inhibits U251 cell proliferation in vivo and exerts acceptable BBB permeability^[1].

Animal Model: Zebrafish wide-type AB strain; 200 CM-Dil labeled U251 cells were transplanted into yolk sac of each wild-type zebrafish embryos at 2 dpf (2 days postfertilization)^[1]

Dosage: 2.50 ng/tail

Administration: Microinjection; 48 h

Result: Remarkably reduced the U251 xenografts fluorescence intensity.

[1]. Yao Feng, et al. Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

necroptosis. Eur J Med Chem. 2022 Feb 5;229:114070.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA